Long-term outcomes after hematopoietic SCT for adult T-cell leukemia/lymphoma: results of prospective trials.
We have previously conducted clinical trials of allogeneic hematopoietic SCT with reduced-intensity conditioning regimen (RIC) for adult T-cell leukemia/lymphoma (ATLL)-a disease caused by human T-lymphotropic virus type 1 (HTLV-1) infection and having a dismal prognosis. Long-term follow-up studies of these trials revealed that 10 of the 29 patients have survived for a median of 82 months (range, 54-100 months) after RIC, indicating a possible curability of the disease by RIC. However, we have also observed that the patterns of post-RIC changes in HTLV-1 proviral load over time among the 10 survivors were classified into three patterns. This is the first report to clarify the long-term outcomes after RIC for ATLL patients.
Choi
I
I
Department of Hematology, National Kyushu Cancer Center, Fukuoka, Japan.
Tanosaki
R
R
Uike
N
N
Utsunomiya
A
A
Tomonaga
M
M
Harada
M
M
Yamanaka
T
T
Kannagi
M
M
Okamura
J
J
D000368:Aged; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation; D015368:Human T-lymphotropic virus 1 / Q000302:isolation & purification; D006801:Humans; D017567:Karnofsky Performance Status; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000628:therapy* / Q000821:virology; D057230:Limit of Detection; D008297:Male; D008875:Middle Aged; D011533:Proviruses / Q000302:isolation & purification; D012074:Remission Induction; D016019:Survival Analysis; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous; D019562:Viral Load